J Gastrointest Cancer. 2021 Jan 05; doi: 10.1007/s12029-020-00580-z. Epub 2021 Jan 05.

Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.

Journal of gastrointestinal cancer

Kaalindi Singh, Arvind Sathyamurthy, Jeba Karunya Ramireddy, Thomas Samuel Ram

PMID: 33400211 DOI: 10.1007/s12029-020-00580-z

Abstract

INTRODUCTION: Chemoradiation is the standard of care in locally advanced carcinoma of the anal canal. However, the irregular surface and elective inguinal treatment poses a challenge for radiation planning and treatment with associated significant toxicity. In this retrospective study, we analysed the outcome of patients treated with intensity-modulated radiation therapy (IMRT) at our centre from 2012 to 2019.

METHODS AND MATERIALS: Records of patients treated with IMRT at our centre from 2012 to 2019 were reviewed. Patients with non-squamous histology and previous irradiation were excluded. Thus, 25 patients were found suitable for the study.

RESULTS: Twenty-five patients with squamous cell carcinoma of the anal canal were treated at our centre from 2012 to 2019 using IMRT based chemoradiation. RTOG guidelines were followed for contouring and Varian Eclipse version 13(Palo Alto, California) was used for planning. Clinical response could be assessed in 20 patients and dosimetric data of all patients was available for review. The target volumes coverage goals as per ICRU 83 were achieved in all patients. The organ at risk constraints for bladder and femoral heads as per LATE-QUANTEC were achieved in most patients; however, the constraints for the rectum, testis and bowel bag were not achieved in the majority of the patients. The median duration of treatment break was 7 days. Mitomycin C and 5-FU or capecitabine were given concurrently with radiation. Eighteen patients (72%) received 2 cycles of chemotherapy, three (12%) received 1 cycle of chemotherapy while 4(16%) patients did not receive any chemotherapy. Median follow-up was 7.5 months. At median follow-up, 15(75%) patients were disease-free and asymptomatic, 2(10%) had residual disease and 3(15%) had progressive disease. Toxicity was assessed using CTCAE Version 5.0. Grade III skin toxicity was reported in 9(36%) of the patients and Grade III gastrointestinal toxicity was reported in 1 (4%) of the patients, no other grades III-IV toxicity was reported. Overall, the disease control was comparable to previous 3D-CRT studies but with much less toxicity.

CONCLUSION: IMRT-based chemoradiation should be the standard of care in locally advanced carcinoma of the anal canal.

Keywords: Anal Canal Cancer; Intensity modulated radiotherapy (IMRT); Squamous cell carcinoma; Volumetric modulated arc therapy (VMAT)

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492 . - PubMed
2. Nigro ND. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum. 1984;27:763–6. - PubMed
3. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33. https://doi.org/10.1016/j.ijrobp.2012.09.023 . - PubMed
4. Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol. 2012;188(1):97–9. - PubMed
5. Marks LB, Yorke ED, Jackson A, ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3):10–S19. https://doi.org/10.1016/j.ijrobp.2009.07.1754 . - PubMed
6. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf - PubMed
7. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8. https://doi.org/10.1038/sj.bjc.6605605 . - PubMed
8. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9. - PubMed
9. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB III, et al. Longterm update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma:survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51. https://doi.org/10.1200/JCO.2012.43.8085 . - PubMed
10. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II):a randomised, phase 3, open-label, 2 _ 2 factorial trial. Lancet Oncol. 2013;14:516–24. https://doi.org/10.1016/S1470-2045(13)70086-X . - PubMed
11. Wright JL, Patil SM, Temple LK, et al. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78(4):1064–72. - PubMed
12. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock JD, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87–04 and 98–11. J Clin Oncol. 2010;28:5061–6. https://doi.org/10.1200/JCO.2010.29.1351 . - PubMed
13. Bellefon M, Lemanski C, Castan F, et al. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: clinical outcomes, patterns of relapse and predictors of failure. Radiother Oncol. 2020;144:141–7. - PubMed

Publication Types

• Journal Article